

Diverticular disease

I. Evidence review: Indications for surgery

NICE guideline

Prognostic evidence review

June 2019

Draft for Consultation

*This evidence review was developed by
the National Guideline Centre*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2019. All rights reserved. Subject to [Notice of rights](#).

Contents

1	Diverticulitis	5
1.1	Review question: What are the indications for surgery in people with complicated acute diverticulitis and acute diverticulitis?.....	5
1.2	Introduction	5
1.3	PICO table.....	5
1.4	Clinical evidence	6
1.4.1	Included studies	6
1.4.2	Excluded studies.....	6
1.4.3	Summary of clinical studies included in the evidence review.....	7
1.4.4	Quality assessment of clinical studies included in the evidence review	7
1.5	Economic evidence	9
1.5.1	Included studies	9
1.5.2	Excluded studies.....	9
1.5.3	Unit costs	9
1.6	Evidence statements	11
1.6.1	Clinical evidence statements.....	11
1.6.2	Health economic evidence statements.....	11
1.7	Recommendations	11
1.8	Rationale and impact.....	11
1.8.1	Why the committee made recommendations	11
1.8.2	Impact of the recommendations on practice.....	11
1.9	The committee’s discussion of the evidence.....	12
1.9.1	Interpreting the evidence.....	12
1.9.2	Cost effectiveness and resource use	12
1.9.3	Other factors the committee took into account	12
	Appendices	18
	Appendix A: Review protocols	18
	Appendix B: Literature search strategies	21
	B.1 Clinical search literature search strategy	22
	B.2 Health Economics literature search strategy.....	25
	Appendix C: Clinical evidence selection.....	31
	Appendix D: Clinical evidence tables	32
	Appendix E: Forest plots.....	34
	Appendix F: GRADE tables	35
	Appendix G: Health economic evidence selection.....	36
	Appendix H: Excluded studies.....	37
	H.1 Excluded clinical studies.....	37

1 Diverticulitis

1.1 Review question: What are the indications for surgery in people with complicated acute diverticulitis and acute diverticulitis?

1.2 Introduction

Diverticulitis is one of the most common reasons for elective bowel resections after cancer. However, there seems to be significant differences between clinicians about how to treat acute diverticulitis. Treatment varies from 'watch and wait', medication and surgery. There are also great variances between clinicians about when to operate, it seems to differ on the number of recurrences, the severity of the condition and how the condition affects the patient's quality of life. Age and comorbidities are also taken into consideration.

This question is aimed to review the evidence and aid the clinician's decision when considering surgery on these patients.

1.3 PICO table

For full details see the review protocol in Appendix A.

Table 1: PICO characteristics of review question

Population	Adults 18 years and over with complicated acute diverticulitis and acute diverticulitis
Prognostic variables under consideration	<ul style="list-style-type: none"> • Complications: <ul style="list-style-type: none"> ○ Perforation ○ Abscess ○ Fistula ○ Stricture ○ Infection • Recurrent episode of acute diverticulitis
Confounding factors	<ul style="list-style-type: none"> • Age • Gender
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Mortality • morbidity • Recurrence rates of acute diverticulitis • Hospitalisation • Need for surgery • Progression of disease/ complications: <ul style="list-style-type: none"> ○ Infections ○ Abscesses ○ Perforation ○ Stricture ○ Fistula
Study design	<ul style="list-style-type: none"> • Prospective and retrospective cohort studies • Randomised controlled trials (if appropriate)

- Systematic reviews of the above

1 1.4 Clinical evidence

2 1.4.1 Included studies

3 One study was included in the review;⁴⁹ this is summarised in Table 2 below. Evidence from
4 this study is summarised in the clinical evidence summary below (Table 3).

5 See also the study selection flow chart in appendix C, study evidence tables in appendix D,
6 forest plots in appendix E and GRADE tables in appendix F.

7 1.4.2 Excluded studies

8 See the excluded studies list in appendix I.

9

10

1.4.3 Summary of clinical studies included in the evidence review

Table 2: Summary of studies included in the evidence review

Study	Population	Analysis	Prognostic variable	Confounders	Outcomes	Limitations
Pittet 2009 ⁴⁹	Single cohort. Consecutive patients with CT diagnosis of diverticulitis. Patients were divided into two groups: those with an initial episode of diverticulitis and those with a recurrence. n=271	Prospective univariate analysis with matched (age and gender) comparison group.	Recurrent diverticulitis	Age Gender	<ul style="list-style-type: none"> • Mortality • Need for surgery • Presence of abscess 	Risk of bias: high Univariate analysis

See appendix D for full evidence tables.

1.4.4 Quality assessment of clinical studies included in the evidence review

Table 3: Clinical evidence summary: Recurrent diverticulitis

Risk factor and outcome (population)	Number of studies	Effect (95% CI)	Imprecision	GRADE Quality
Mortality	1	Peto OR: 0.25 (95% CI 0.04 to 1.63) ^a	Serious ^b	LOW
Surgery	1	OR: 3.06 (95% CI 1.04 to 8.99) ^a	None	MODERATE
Presence of abscess	1	OR: 1.11 (95% CI 0.51 to 2.4) ^a	Serious ^b	LOW

Risk factor and outcome (population)	Number of studies	Effect (95% CI)	Imprecision	GRADE Quality
--------------------------------------	-------------------	-----------------	-------------	---------------

1 (a) *Methods: univariate analysis, the two groups were similar regarding age and sex ratio.*
 2 (b) *Imprecision was considered serious if the confidence intervals crossed the line of null effect.*

3 See appendix F for full GRADE tables.

1 1.5 Economic evidence

2 1.5.1 Included studies

3 No relevant health economic studies were identified.

4 1.5.2 Excluded studies

5 No health economic studies that were relevant to this question were excluded due to
6 assessment of limited applicability or methodological limitations.

7 See also the health economic study selection flow chart in appendix G

8 1.5.3 Unit costs

9 The unit costs below were presented to the Committee, to aid consideration of cost
10 effectiveness.

11 **Table 4: NHS cost of non-elective sigmoid resection**

Procedure (OPCS4)	Healthcare Resource Group (HRG) code and description	Unit Cost	Average Length of Stay	Source
Sigmoid colectomy and anastomosis	FF33 Distal Colon Procedures, 19 years and over, inclusive of non-elective short stay and non-elective long stay with excess bed days, weighted for complications and co morbidities for HRG codes: FF33A and FF33B; as recorded for Non-Elective Inpatients	£7,091	9.0 days	NHS Reference Costs 2016-2017
Sigmoid colectomy and ileostomy HFQ Or Sigmoid colectomy and exteriorisation of bowel NEC	FF31 Complex Large Intestine Procedures, 19 years and over, inclusive of non-elective short stay and non-elective long stay with excess bed days, weighted for complications and co morbidities for HRG codes: FF31A, FF31B, FF31C and FF31D; as recorded for Non-Elective Inpatients	£8,312	11.0 days	NHS Reference Costs 2016-2017

12
13

1

2

Table 5: NHS cost of elective sigmoid resection

	Currency Description	Unit Cost	Average Length of Stay	Source
Sigmoid colectomy and anastomosis	FF33 Distal Colon Procedures, 19 years and over, inclusive of excess bed days, weighted for complications and co morbidities for HRG codes: FF33A and FF33B; as recorded for Elective Inpatients	£6,487	5.2 days	NHS Reference Costs 2016-2017
Sigmoid colectomy and ileostomy HFQ Or Sigmoid colectomy and exteriorisation of bowel NEC	FF31 Complex Large Intestine Procedures, 19 years and over, inclusive of excess bed days, weighted for complications and co morbidities for HRG codes: FF31A, FF31B, FF31C and FF31D; as recorded for Elective Inpatients	£8,140	7.6 days	NHS Reference Costs 2016-2017
Closure of ileostomy	FF22 Major Small Intestine Procedures, 19 years and over, inclusive of excess bed days, weighted for complications and co morbidities for HRG codes: FF22A, FF22B, FF22C and FF22C; as recorded for Elective Inpatients	£5,151	5.97 days	NHS Reference Costs 2016-2017

3

4

1

2 **1.6 Evidence statements**

3 **1.6.1 Clinical evidence statements**

4 One study reported on the association between recurrent episodes of diverticulitis and
5 indications for surgery. The evidence suggested that recurrent diverticulitis was a possible
6 indication for surgery when looking at the outcome need for surgery (n=271, moderate
7 quality). However this was not consistent with the outcomes mortality and presence of an
8 abscess on CT scan which suggested no association (low quality, n= 271).

9 **1.6.2 Health economic evidence statements**

10 No relevant economic evaluations were identified.

11 **1.7 Recommendations**

12 **Symptoms and signs of complicated acute diverticulitis**

13 11. Suspect a complication of diverticulitis and refer for same-day hospital assessment if the
14 person has uncontrolled abdominal pain and any of the features in table 6

15 **Table 6: Symptoms and signs that suggest a complication of diverticulitis**

Sign or symptom	Possible cause
Abdominal mass on examination or peri-rectal fullness on internal rectal examination	Intra-abdominal abscess
Abdominal rigidity, guarding and rebound tenderness on examination	Bowel perforation and peritonitis
Altered mental state, raised respiratory rate, low systolic blood pressure, raised heart rate, low tympanic temperature, no urine output or skin discolouration	Sepsis
Faecaluria, pneumaturia or pyuria	Fistula
Colicky abdominal pain, absolute constipation (passage of no flatus or stool), vomiting or abdominal distention	Intestinal obstruction

16 **1.8 Rationale and impact**

17 **1.8.1 Why the committee made recommendations**

18 There was no relevant evidence on symptoms and signs of complicated acute diverticulitis,
19 so a recommendation was made using formal consensus methods (please see Methods
20 Chapter R). The recommendation focused on symptoms and signs that differentiated
21 uncomplicated from complicated acute diverticulitis; if any of these symptoms and signs are
22 present, same-day hospital assessment is necessary. This recommendation is consistent
23 with current practice.

24 **1.8.2 Impact of the recommendation on practice**

25 The recommendation reflects current practice.

1.9 The committee's discussion of the evidence

1.9.1 Interpreting the evidence

1.9.1.1 The outcomes that matter most

The guideline committee identified the following outcomes as critical outcomes for this review; mortality, morbidity, recurrence rates of acute diverticulitis, hospitalisation, need for surgery, progression of disease and complications including, infections, abscesses, perforation, stricture and fistula. Evidence from a single study was found for only three of the outcomes; mortality, need for surgery and presence of abscess.

1.9.1.2 The quality of the evidence

The quality of the evidence included was medium to low due to a high risk of bias from a single study with only a univariate analysis.

1.9.1.3 Benefits and harms

Only one study was identified comparing patients who had an initial episode of acute diverticulitis to those who had a recurrent episode. The committee were unable to make any evidence based recommendations on this subject and therefore statements were included in the Delphi survey. The current guidance for surgery in patients with recurrent episodes of acute diverticulitis is to take a tailored approach to each individual patient as outlined by the ACPGBI guidance in 2008. NO further clear indications for surgery in this patient group could be identified. A further group identified for surgery were those who had been treated for complications of acute diverticulitis conservatively but no evidence was found on subsequent surgical management of these patients with regard to indications for surgery.

The current evidence did not sufficiently address the harms and benefits associated with clear indications for surgery.

1.9.2 Cost effectiveness and resource use

No relevant economic evaluations were identified which address the indications for surgery in people with acute diverticulitis. The Committee were presented with unit costs associated with surgery.

The clinical evidence was not sufficient for the Committee to make a recommendation.

1.9.3 Other factors the committee took into account

The committee noted the main symptoms and signs associated with complicated acute diverticulitis. A person with a fistula may develop faecaluria (faeces in urine), pneumaturia (gas or air in urine) or pyuria (white blood cells or pus in urine). A stricture may lead to obstructive symptoms with complaints of nausea, vomiting and distension being present. Signs of sepsis including raised or lowered temperature or change in conscious level may also be present.

Statements were included in the Delphi survey on the symptoms and signs specific to complicated acute diverticulitis, namely abscess, perforation, fistula and intestinal obstruction. The committee also noted the importance of a statement on symptoms and signs of sepsis. The statement was modified after voting to be consistent with the NICE guideline on Sepsis (NG51).

All of the statements reached consensus in the first round.

- 1 Same day hospital assessment was recommended if any of the symptoms and signs of
- 2 complicated acute diverticulitis are present.
- 3

References

1. Abbas S. Resection and primary anastomosis in acute complicated diverticulitis, a systematic review of the literature. *International Journal of Colorectal Disease*. 2007; 22(4):351-357
2. Alvarez JA, Baldonado RF, Bear IG, Otero J, Pire G, Alvarez P et al. Outcome and prognostic factors of morbidity and mortality in perforated sigmoid diverticulitis. *International Surgery*. 2009; 94(3):240-8
3. Ambrosetti P, Morel P. Acute left colonic diverticulitis: Indications for operation and predictive parameters of early and late medical treatment failure: A prospective non-randomized study of 423 patients. *Digestive Surgery*. 1996; 13(4-5):349-352
4. Ambrosetti P, Robert JH, Witzig JA, Mirescu D, Mathey P, Borst F et al. Acute left colonic diverticulitis: a prospective analysis of 226 consecutive cases. *Surgery*. 1994; 115(5):546-50
5. Ames JT, Federle MP, Pealer KM. Perforated duodenal diverticulum: clinical and imaging findings in eight patients. *Abdominal Imaging*. 2009; 34(2):135-9
6. Amin M, Nallinger R, Polk HC, Jr. Conservative treatment of selected patients with colovesical fistula due to diverticulitis. *Surgery, Gynecology and Obstetrics*. 1984; 159(5):442-4
7. Andeweg CS, Berg R, Staal JB, ten Broek RP, van Goor H. Patient-reported outcomes after conservative or surgical management of recurrent and chronic complaints of diverticulitis: Systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*. 2016; 14(2):183-90
8. Anonymous. Researchers assess optimal timing of surgery following one or more attacks of uncomplicated diverticulitis. Rockville, Maryland. 2002.
9. Aydinli HH, Benlice C, Ozuner G, Gorgun E, Abbas MA. Risk factors associated with postoperative morbidity in over 500 colovesical fistula patients undergoing colorectal surgery: a retrospective cohort study from ACS-NSQIP database. *International Journal of Colorectal Disease*. 2017; 32(4):469-474
10. Bauer VP. Emergency management of diverticulitis. *Clinics in Colon and Rectal Surgery*. 2009; 22(3):161-8
11. Bielecki K, Kaminski P, Klukowski M. Large bowel perforation: morbidity and mortality. *Techniques in Coloproctology*. 2002; 6(3):177-82
12. Biondo S, Borao JL, Kreisler E, Golda T, Millan M, Frago R et al. Recurrence and virulence of colonic diverticulitis in immunocompromised patients. *American Journal of Surgery*. 2012; 204(2):172-9
13. Bohm SK. Risk factors for diverticulosis, diverticulitis, diverticular perforation, and bleeding: A plea for more subtle history taking. *Viszeralmedizin*. 2015; 31(2):84-94
14. Bolkenstein HE, van de Wall BJM, Consten ECJ, Broeders I, Draaisma WA. Risk factors for complicated diverticulitis: systematic review and meta-analysis. *International Journal of Colorectal Disease*. 2017; 32:1375-83

- 1 15. Broderick-Villa G, Burchette RJ, Collins JC, Abbas MA, Haigh PI. Hospitalization for
2 acute diverticulitis does not mandate routine elective colectomy. *Archives of Surgery*.
3 2005; 140(6):576-83
- 4 16. Carpenter WS, Allaben RD, Kambouris AA. Fistulas complicating diverticulitis of the
5 colon. *Surgery, Gynecology and Obstetrics*. 1972; 134(4):625-8
- 6 17. Ceresoli M, Coccolini F, Ansaloni L. 12 months results of laparoscopic lavage in
7 perforated acute diverticulitis - update of meta-analysis results new evidences, which
8 perspectives? *The Journal of Trauma and Acute Care Surgery*. 2017; 83(6):1215-
9 1216
- 10 18. Chapman J, Davies M, Wolff B, Dozois E, Tessier D, Harrington J et al. Complicated
11 diverticulitis: is it time to rethink the rules? *Annals of Surgery*. 2005; 242(4):576-81;
12 discussion 581-3
- 13 19. Chapman JR, Dozois EJ, Wolff BG, Gullerud RE, Larson DR. Diverticulitis: a
14 progressive disease? Do multiple recurrences predict less favorable outcomes?
15 *Annals of Surgery*. 2006; 243(6):876-830; discussion 880-3
- 16 20. Chiu PW, Lam CY, Chow TL, Kwok SP. Conservative approach is feasible in the
17 management of acute diverticulitis of the right colon. *ANZ Journal of Surgery*. 2001;
18 71(11):634-6
- 19 21. Damle RN, Cherng NB, Flahive JM, Davids JS, Maykel JA, Sturrock PR et al. Clinical
20 and financial impact of hospital readmissions after colorectal resection: predictors,
21 outcomes, and costs. *Diseases of the Colon and Rectum*. 2014; 57(12):1421-9
- 22 22. Deenichin GP, Dimov RS, Stefanov CS, Dimova RT. Acute perforated diverticulitis of
23 the colon as a rare cause for development of abdominal compartment syndrome.
24 *Folia Medica (Plovdiv)*. 2008; 50(2):32-6
- 25 23. Elliott TB, Yego S, Irvin TT. Five-year audit of the acute complications of diverticular
26 disease. *British Journal of Surgery*. 1997; 84(4):535-9
- 27 24. Gala T, Alvi AR, Sheikh GM, Habib HY, Ghafoor Z, Mir TA et al. Experience of
28 managing complicated diverticulitis of colon: a retrospective case series from South
29 Asian country. *Journal of the Pakistan Medical Association*. 2014; 64(4):409-14
- 30 25. Garfinkle R, Kugler A, Pelsser V, Vasilevsky CA, Morin N, Gordon P et al. Diverticular
31 abscess managed with long-term definitive nonoperative intent is safe. *Diseases of
32 the Colon and Rectum*. 2016; 59(7):648-55
- 33 26. Gregersen R, Andresen K, Burcharth J, Pommergaard HC, Rosenberg J. Short-term
34 mortality, readmission, and recurrence in treatment of acute diverticulitis with abscess
35 formation: a nationwide register-based cohort study. *International Journal of
36 Colorectal Disease*. 2016; 31(5):983-90
- 37 27. Haglund U, Hellberg R, Johnsen C, Hulten L. Complicated diverticular disease of the
38 sigmoid colon. An analysis of short and long term outcome in 392 patients. *Annales
39 Chirurgiae et Gynaecologiae*. 1979; 68(2):41-6
- 40 28. Himal HS, Ashby DB, Duignan JP, Richardson DM, Miller JL, MacLean LD.
41 Management of perforating diverticulitis of the colon. *Surgery, Gynecology and
42 Obstetrics*. 1977; 144(2):225-6
- 43 29. Howe HJ, Casali RE, Westbrook KC, Thompson BW, Read RC. Acute perforations of
44 the sigmoid colon secondary to diverticulitis. *American Journal of Surgery*. 1979;
45 137(2):184-7

- 1 30. Hussain A, Mahmood H, Subhas G, El-Hasani S. Complicated diverticular disease of
2 the colon, do we need to change the classical approach, a retrospective study of 110
3 patients in southeast England. *World Journal of Emergency Surgery*. 2008; 3:5
- 4 31. Isbister WH. The management of colorectal perforation and peritonitis. *Australian and
5 New Zealand Journal of Surgery*. 1997; 67(11):804-8
- 6 32. Jalouta T, Jrebi N, Luchtefeld M, Ogilvie JW, Jr. Diverticulitis recurrence after
7 percutaneous abscess drainage. *International Journal of Colorectal Disease*. 2017;
8 32(10):1367-1373
- 9 33. Jamal Talabani A, Lydersen S, Ness-Jensen E, Endreseth BH, Edna TH. Risk factors
10 of admission for acute colonic diverticulitis in a population-based cohort study: The
11 North Trondelag Health Study, Norway. *World Journal of Gastroenterology*. 2016;
12 22(48):10663-10672
- 13 34. Janes S, Meagher A, Faragher IG, Shedda S, Frizelle FA. The place of elective
14 surgery following acute diverticulitis in young patients: when is surgery indicated? An
15 analysis of the literature. *Diseases of the Colon and Rectum*. 2009; 52(5):1008-16
- 16 35. Kaewlai R, Nazinitsky KJ. Acute colonic diverticulitis in a community-based hospital:
17 CT evaluation in 138 patients. *Emergency Radiology*. 2007; 13(4):171-179
- 18 36. Kakodkar R, Gupta S, Nundy S. Complicated colonic diverticulosis: surgical
19 perspective from an Indian Centre. *Tropical Gastroenterology*. 2005; 26(3):152-5
- 20 37. Kiani QH, George ML, Carapeti EA, Schizas AM, Williams AB. Colovesical fistula:
21 should it be considered a single disease? *Annals of Coloproctology*. 2015; 31(2):57-
22 62
- 23 38. Kronborg O. Treatment of perforated sigmoid diverticulitis: a prospective randomized
24 trial. *British Journal of Surgery*. 1993; 80(4):505-507
- 25 39. Ladwa N, Sajid M, McFall M, Miles A, Sains P, Baig MK. The investigation and
26 management of colovesical fistulae in the modern era-a single institutions 12-year
27 experience. *Gut*. 2012; 61(Suppl 2):A336
- 28 40. Lahat A, Avidan B, Sakhnini E, Katz L, Fidder HH, Meir SB. Acute diverticulitis: a
29 decade of prospective follow-up. *Journal of Clinical Gastroenterology*. 2013;
30 47(5):415-9
- 31 41. Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, Ponce M, Quintero E, Perez-Aisa MA
32 et al. The changing face of hospitalisation due to gastrointestinal bleeding and
33 perforation. *Alimentary Pharmacology and Therapeutics*. 2011; 33(5):585-591
- 34 42. Medina VA, Papanicolaou GK, Tadros RR, Fielding LP. Acute perforated diverticulitis:
35 primary resection and anastomosis? *Connecticut Medicine*. 1991; 55(5):258-61
- 36 43. National Institute for Health and Care Excellence. Developing NICE guidelines: the
37 manual. London. National Institute for Health and Care Excellence, 2014. Available
38 from:
39 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
- 40 44. Nelson RS, Ewing BM, Wengert TJ, Thorson AG. Clinical outcomes of complicated
41 diverticulitis managed nonoperatively. *American Journal of Surgery*. 2008;
42 196(6):969-72; discussion 973-4
- 43 45. Niebling M, van Nunspeet L, Zwaving H, Eddes EH, Bosker R, Eeftink Schattenkerk
44 M. Management of colovesical fistulae caused by diverticulitis: 12 years of experience
45 in one medical centre. *Acta Chirurgica Belgica*. 2013; 113(1):30-4

- 1 46. Nishikawa H, Maruo T, Tsumura T, Sekikawa A, Kanesaka T, Osaki Y. Risk factors
2 associated with recurrent hemorrhage after the initial improvement of colonic
3 diverticular bleeding. *Acta Gastroenterologica Belgica*. 2013; 76(1):20-4
- 4 47. Nord CE. Treatment of intraabdominal infections: Worldwide clinical trials. *Infectious
5 Diseases in Clinical Practice*. 1995; 4(Suppl. 1):S17-S25
- 6 48. O'Leary DP, Myers E, O'Brien O, Andrews E, McCourt M, Redmond HP. Persistent
7 perforation in non-faeculant diverticular peritonitis--incidence and clinical significance.
8 *Journal of Gastrointestinal Surgery*. 2013; 17(2):369-73
- 9 49. Pittet O, Kotzampassakis N, Schmidt S, Denys A, Demartines N, Calmes JM.
10 Recurrent left colonic diverticulitis episodes: more severe than the initial diverticulitis?
11 *World Journal of Surgery*. 2009; 33(3):547-52
- 12 50. Rahbour G, Gabe SM, Ullah MR, Thomas GP, Al-Hassi HO, Yassin NA et al. Seven-
13 year experience of enterocutaneous fistula with univariate and multivariate analysis of
14 factors associated with healing: Development of a validated scoring system.
15 *Colorectal Disease*. 2013; 15(9):1162-1170
- 16 51. Shah AM, Malhotra A, Patel B, Spira R, DePasquale JR, Baddoura W. Acute
17 diverticulitis in the young: a 5-year retrospective study of risk factors, clinical
18 presentation and complications. *Colorectal Disease*. 2011; 13(10):1158-61
- 19 52. Solkar MH, Forshaw MJ, Sankararajah D, Stewart M, Parker MC. Colovesical fistula -
20 Is a surgical approach always justified? *Colorectal Disease*. 2005; 7(5):467-471
- 21 53. Soreide K, Boermeester MA, Humes DJ, Velmahos GC. Acute colonic diverticulitis:
22 modern understanding of pathomechanisms, risk factors, disease burden and
23 severity. *Scandinavian Journal of Gastroenterology*. 2016; 51(12):1416-1422
- 24 54. Thorson CM, Paz Ruiz PS, Roeder RA, Sleeman D, Casillas VJ. The perforated
25 duodenal diverticulum. *Archives of Surgery*. 2012; 147(1):81-8
- 26 55. Vasilevsky CA, Belliveau P, Trudel JL, Stein BL, Gordon PH. Fistulas complicating
27 diverticulitis. *International Journal of Colorectal Disease*. 1998; 13(2):57-60
- 28 56. Vinas-Salas J, Villalba-Acosta J, Scaramucci M, Rodas JH, Rodriguez G, Tiziana
29 Ciutto S et al. Complications of colonic diverticular disease. Comparative study of two
30 series. *Revista Española de Enfermedades Digestivas*. 2001; 93(10):649-58
- 31 57. Wood CD. Acute perforations of the colon. *Diseases of the Colon and Rectum*. 1977;
32 20(2):126-9

33

34

1 **Appendices**
2 **Appendix A: Review protocols**

3 **Table 7: Review protocol: Indications for surgery for acute diverticulitis**

Field	Content
Review question	What are the indications for surgery in people with complicated acute diverticulitis and acute diverticulitis?
Type of review question	Prognostic review A review of health economic evidence related to the same review question was conducted in parallel with this review. For details, see the health economic review protocol for this NICE guideline.
Objective of the review	To determine the criteria which indicate that surgery is appropriate in people with acute diverticulitis.
Eligibility criteria – population / disease / condition / issue / domain	Adults 18 years and over with complicated acute diverticulitis and acute diverticulitis
Eligibility criteria – intervention(s) / exposure(s) / prognostic factor(s)	<ul style="list-style-type: none"> • Complications: <ul style="list-style-type: none"> ○ Perforation ○ Abscess ○ Fistula ○ Stricture ○ Infection • Recurrent episode of acute diverticulitis
Eligibility criteria – confounders	<ul style="list-style-type: none"> • Age • Gender
Outcomes and prioritisation	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Mortality • morbidity • Recurrence rates of acute diverticulitis • Hospitalisation • Need for surgery • Progression of disease/ complications: <ul style="list-style-type: none"> ○ Infections ○ Abscesses ○ Perforation ○ Stricture ○ Fistula
Eligibility criteria – study design	<p>RCT Systematic review Cohort studies</p> <p>Note: in the absence of evidence, cross-sectional studies and case series will be considered.</p>

Other inclusion exclusion criteria	Exclusions: <ul style="list-style-type: none"> • Children and young people aged 17 years and younger • Prevention
Proposed sensitivity / subgroup analysis, or meta-regression	Strata: Subgroups: <ul style="list-style-type: none"> • People of Asian family origin as they are known to develop right-sided diverticula
Selection process – duplicate screening / selection / analysis	Studies are sifted by title and abstract. Potentially significant publications obtained in full text are then assessed against the inclusion criteria specified in this protocol.
Data management (software)	<ul style="list-style-type: none"> • Pairwise meta-analyses performed using Cochrane Review Manager (RevMan5). • GRADEpro used to assess the quality of evidence for each outcome • Bibliographies, citations and study sifting managed using EndNote • Data extractions performed using EviBase, a platform designed and maintained by the National Guideline Centre (NGC)
Information sources – databases and dates	Medline, Embase, The Cochrane Library
Identify if an update	Not applicable
Author contacts	https://www.nice.org.uk/guidance/conditions-and-diseases/digestive-tract-conditions/diverticular-disease
Highlight if amendment to previous protocol	For details, please see section 4.5 of Developing NICE guidelines: the manual.
Search strategy – for one database	For details, please see appendix B
Data collection process – forms / duplicate	A standardised evidence table format will be used, and published as appendix D of the evidence report.
Data items – define all variables to be collected	For details, please see evidence tables in Appendix D (clinical evidence tables) or H (health economic evidence tables).
Methods for assessing bias at outcome / study level	Standard study checklists were used to critically appraise individual studies. For details please see section 6.2 of Developing NICE guidelines: the manual The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group http://www.gradeworkinggroup.org/
Criteria for quantitative synthesis	For details, please see section 6.4 of Developing NICE guidelines: the manual.
Methods for quantitative analysis – combining studies and exploring (in)consistency	For details, please see the separate Methods report (Chapter R) for this guideline.
Meta-bias assessment –	For details, please see section 6.2 of Developing NICE guidelines: the manual.

publication bias, selective reporting bias	
Confidence in cumulative evidence	For details, please see sections 6.4 and 9.1 of Developing NICE guidelines: the manual.
Rationale / context – what is known	For details, please see the introduction to the evidence review.
Describe contributions of authors and guarantor	A multidisciplinary committee developed the evidence review. The committee was convened by the National Guideline Centre (NGC) and chaired by James Dalrymple in line with section 3 of Developing NICE guidelines: the manual. Staff from NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details, please see Developing NICE guidelines: the manual.
Sources of funding / support	The NGC is funded by NICE and hosted by the Royal College of Physicians.
Name of sponsor	The NGC is funded by NICE and hosted by the Royal College of Physicians.
Roles of sponsor	NICE funds the NGC to develop guidelines for those working in the NHS, public health and social care in England.
PROSPERO registration number	Not registered

1

Table 8: Health economic review protocol

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2002, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).⁴³</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.

- If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.
- If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or both then there is discretion over whether it should be included.

Where there is discretion

The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2002 or later but that depend on unit costs and resource data entirely or predominantly from before 2002 will be rated as 'Not applicable'.
- Studies published before 2002 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

1

2

Appendix B: Literature search strategies

3

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 2014, updated 2017

4

5

For more detailed information, please see the Methodology Review.

1 B.1 Clinical search literature search strategy

2 Searches were constructed without Prognostic/risk factor terms using the following approach:

- 3
- Population AND Study filter(s)

4 **Table 9: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 13 November 2018	Exclusions Randomised controlled trials Systematic review studies Observational studies
Embase (OVID)	1974 – 13 November 2018	Exclusions Randomised controlled trials Systematic review studies Observational studies
The Cochrane Library (Wiley)	Cochrane Reviews to 2018 Issue 11 of 12 CENTRAL to 2018 Issue 11 of 12 DARE, and NHSEED to 2015 Issue 2 of 4 HTA to 2016 Issue 2 of 4	None

5 **Table 10: Medline (Ovid) search terms**

1.	diverticul*.mp.
2.	limit 1 to English language
3.	letter/
4.	editorial/
5.	news/
6.	exp historical article/
7.	Anecdotes as Topic/
8.	comment/
9.	case report/
10.	(letter or comment*).ti.
11.	or/3-10
12.	randomized controlled trial/ or random*.ti,ab.
13.	11 not 12
14.	animals/ not humans/
15.	exp Animals, Laboratory/
16.	exp Animal Experimentation/
17.	exp Models, Animal/
18.	exp Rodentia/
19.	(rat or rats or mouse or mice).ti.
20.	or/13-19
21.	2 not 20
22.	randomized controlled trial.pt.
23.	controlled clinical trial.pt.

24.	randomi#ed.ti,ab.
25.	placebo.ab.
26.	randomly.ti,ab.
27.	Clinical Trials as topic.sh.
28.	trial.ti.
29.	or/22-28
30.	Meta-Analysis/
31.	exp Meta-Analysis as Topic/
32.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
33.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
34.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
35.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
36.	(search* adj4 literature).ab.
37.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
38.	cochrane.jw.
39.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
40.	or/50-59
41.	Epidemiologic studies/
42.	Observational study/
43.	exp Cohort studies/
44.	(cohort adj (study or studies or analys* or data)).ti,ab.
45.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
46.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
47.	Controlled Before-After Studies/
48.	Historically Controlled Study/
49.	Interrupted Time Series Analysis/
50.	(before adj2 after adj2 (study or studies or data)).ti,ab.
51.	or/30-39
52.	exp case control study/
53.	case control*.ti,ab.
54.	or/41-42
55.	40 or 43
56.	Cross-sectional studies/
57.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
58.	or/45-46
59.	40 or 47
60.	40 or 43 or 47
61.	21 and (29 or 40 or 60)

1

Table 11: Embase (Ovid) search terms

1.	diverticul*.mp.
2.	limit 1 to English language
3.	letter.pt. or letter/

4.	note.pt.
5.	editorial.pt.
6.	case report/ or case study/
7.	(letter or comment*).ti.
8.	or/3-7
9.	randomized controlled trial/ or random*.ti,ab.
10.	8 not 9
11.	animal/ not human/
12.	nonhuman/
13.	exp Animal Experiment/
14.	exp Experimental Animal/
15.	animal model/
16.	exp Rodent/
17.	(rat or rats or mouse or mice).ti.
18.	or/10-17
19.	2 not 18
20.	random*.ti,ab.
21.	factorial*.ti,ab.
22.	(crossover* or cross over*).ti,ab.
23.	((doubl* or singl*) adj blind*).ti,ab.
24.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
25.	crossover procedure/
26.	single blind procedure/
27.	randomized controlled trial/
28.	double blind procedure/
29.	or/20-28
30.	systematic review/
31.	meta-analysis/
32.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
33.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
34.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
35.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
36.	(search* adj4 literature).ab.
37.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
38.	cochrane.jw.
39.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
40.	or/30-39
41.	Clinical study/
42.	Observational study/
43.	family study/
44.	longitudinal study/
45.	retrospective study/
46.	prospective study/

47.	cohort analysis/
48.	follow-up/
49.	cohort*.ti,ab.
50.	48 and 49
51.	(cohort adj (study or studies or analys* or data)).ti,ab.
52.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
53.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
54.	(before adj2 after adj2 (study or studies or data)).ti,ab.
55.	or/41-47,50-54
56.	exp case control study/
57.	case control*.ti,ab.
58.	or/56-57
59.	55 or 58
60.	cross-sectional study/
61.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
62.	or/60-61
63.	55 or 62
64.	55 or 58 or 62
65.	19 and (29 or 40 and 64)

1 **Table 12: Cochrane Library (Wiley) search terms**

#1.	diverticul*.mp.
-----	-----------------

2 **B.2 Health Economics literature search strategy**

3 Health economic evidence was identified by conducting a broad search relating to
4 Diverticular Disease population in NHS Economic Evaluation Database (NHS EED – this
5 ceased to be updated after March 2015) and the Health Technology Assessment database
6 (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for
7 Research and Dissemination (CRD). Additional searches were run on Medline and Embase
8 for health economics, economic modelling and quality of life studies.

9 **Table 13: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline	1946 – 13 November 2018	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Embase	1974 – 13 November 2018	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 13 November 2018 NHSEED - Inception to March	None

Database	Dates searched	Search filter used
	2015	

1

Table 14: Medline (Ovid) search terms

1.	diverticul*.mp.
2.	limit 1 to English language
3.	letter/
4.	editorial/
5.	news/
6.	exp historical article/
7.	Anecdotes as Topic/
8.	comment/
9.	case report/
10.	(letter or comment*).ti.
11.	or/3-10
12.	randomized controlled trial/ or random*.ti,ab.
13.	11 not 12
14.	animals/ not humans/
15.	exp Animals, Laboratory/
16.	exp Animal Experimentation/
17.	exp Models, Animal/
18.	exp Rodentia/
19.	(rat or rats or mouse or mice).ti.
20.	or/13-19
21.	2 not 20
22.	Economics/
23.	Value of life/
24.	exp "Costs and Cost Analysis"/
25.	exp Economics, Hospital/
26.	exp Economics, Medical/
27.	Economics, Nursing/
28.	Economics, Pharmaceutical/
29.	exp "Fees and Charges"/
30.	exp Budgets/
31.	budget*.ti,ab.
32.	cost*.ti.
33.	(economic* or pharmaco?economic*).ti.
34.	(price* or pricing*).ti,ab.
35.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
36.	(financ* or fee or fees).ti,ab.
37.	(value adj2 (money or monetary)).ti,ab.
38.	or/22-37
39.	exp models, economic/

40.	*Models, Theoretical/
41.	markov chains/
42.	monte carlo method/
43.	exp Decision Theory/
44.	(markov* or monte carlo).ti,ab.
45.	econom* model*.ti,ab.
46.	(decision* adj2 (tree* or analy* or model*)).ti,ab.
47.	Models, Organizational/
48.	*models, statistical/
49.	*logistic models/
50.	models, nursing/
51.	((organi?ation* or operation* or service* or concept*) adj3 (model* or map* or program* or simulation* or system* or analys*)).ti,ab.
52.	(econom* adj2 (theor* or system* or map* or evaluat*)).ti,ab.
53.	(SSM or SODA).ti,ab.
54.	(strateg* adj3 (option* or choice*) adj3 (analys* or decision*)).ti,ab.
55.	soft systems method*.ti,ab.
56.	(Meta-heuristic* or Metaheuristic*).ti,ab.
57.	(dynamic* adj2 (model* or system*)).ti,ab.
58.	(simulation adj3 (model* or discrete event* or agent)).ti,ab.
59.	(microsimulation* or "micro* simulation*").ti,ab.
60.	((flow or core) adj2 model*).ti,ab.
61.	(data adj2 envelopment*).ti,ab.
62.	system* model*.ti,ab.
63.	or/41-64
64.	quality-adjusted life years/
65.	sickness impact profile/
66.	(quality adj2 (wellbeing or well being)).ti,ab.
67.	sickness impact profile.ti,ab.
68.	disability adjusted life.ti,ab.
69.	(qal* or qtime* or qwb* or daly*).ti,ab.
70.	(euroqol* or eq5d* or eq 5*).ti,ab.
71.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
72.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
73.	(hui or hui1 or hui2 or hui3).ti,ab.
74.	(health* year* equivalent* or hye or hyes).ti,ab.
75.	discrete choice*.ti,ab.
76.	rosser.ti,ab.
77.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
78.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
79.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
80.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
81.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
82.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
83.	or/22-40

84.	21 and (38 or 63 or 83)
-----	-------------------------

1

Table 15: Embase (Ovid) search terms

1.	diverticul*.mp.
2.	limit 1 to English language
3.	letter.pt. or letter/
4.	note.pt.
5.	editorial.pt.
6.	case report/ or case study/
7.	(letter or comment*).ti.
8.	or/3-7
9.	randomized controlled trial/ or random*.ti,ab.
10.	8 not 9
11.	animal/ not human/
12.	nonhuman/
13.	exp Animal Experiment/
14.	exp Experimental Animal/
15.	animal model/
16.	exp Rodent/
17.	(rat or rats or mouse or mice).ti.
18.	or/10-17
19.	2 not 18
20.	Economics/
21.	Value of life/
22.	exp "Costs and Cost Analysis"/
23.	exp Economics, Hospital/
24.	exp Economics, Medical/
25.	Economics, Nursing/
26.	Economics, Pharmaceutical/
27.	exp "Fees and Charges"/
28.	exp Budgets/
29.	budget*.ti,ab.
30.	cost*.ti.
31.	(economic* or pharmaco?economic*).ti.
32.	(price* or pricing*).ti,ab.
33.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
34.	(financ* or fee or fees).ti,ab.
35.	(value adj2 (money or monetary)).ti,ab.
36.	or/20-35
37.	statistical model/

38.	*theoretical model/
39.	nonbiological model/
40.	stochastic model/
41.	decision theory/
42.	decision tree/
43.	exp nursing theory/
44.	monte carlo method/
45.	(markov* or monte carlo).ti,ab.
46.	econom* model*.ti,ab.
47.	(decision* adj2 (tree* or analy* or model*)).ti,ab.
48.	((organi?ation* or operation* or service* or concept*) adj3 (model* or map* or program* or simulation* or system* or analys*)).ti,ab.
49.	(econom* adj2 (theor* or system* or map* or evaluat*)).ti,ab.
50.	(SSM or SODA).ti,ab.
51.	(strateg* adj3 (option* or choice*) adj3 (analys* or decision*)).ti,ab.
52.	soft systems method*.ti,ab.
53.	(Meta-heuristic* or Metaheuristic*).ti,ab.
54.	(dynamic* adj2 (model* or system*)).ti,ab.
55.	(simulation adj3 (model* or discrete event* or agent)).ti,ab.
56.	(microsimulation* or "micro* simulation*").ti,ab.
57.	((flow or core) adj2 model*).ti,ab.
58.	(data adj2 envelopment*).ti,ab.
59.	system* model*.ti,ab.
60.	or/39-61
61.	quality adjusted life year/
62.	"quality of life index"/
63.	short form 12/ or short form 20/ or short form 36/ or short form 8/
64.	sickness impact profile/
65.	(quality adj2 (wellbeing or well being)).ti,ab.
66.	sickness impact profile.ti,ab.
67.	disability adjusted life.ti,ab.
68.	(qal* or qtime* or qwb* or daly*).ti,ab.
69.	(euroqol* or eq5d* or eq 5*).ti,ab.
70.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
71.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
72.	(hui or hui1 or hui2 or hui3).ti,ab.
73.	(health* year* equivalent* or hye or hyes).ti,ab.
74.	discrete choice*.ti,ab.
75.	rosser.ti,ab.
76.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.

77.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
78.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
79.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
80.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
81.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
82.	or/20-40
83.	19 and (36 or 60 or 82)

1

Table 16: NHS EED and HTA (CRD) search terms

#1.	diverticul*
-----	-------------

2


3

4

1

Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of indications for surgery.



2

3

Appendix D: Clinical evidence tables

Table 17: Clinical evidence tables

Reference	Pittet 2009 ⁴⁹
Study type and analysis	Cohort; prospective analysis with matched (age and gender) comparison group.
Number of participants and characteristics	<p>All consecutive patients with a diagnosis of diverticulitis on their CT report at admission and those with a final diagnosis of diverticulitis on their discharge summary. Patients were divided into two groups: those with an initial episode of diverticulitis and those with a recurrence. Recurrence was defined as a new episode of diverticulitis provided a previous CT scan confirmed the first episode.</p> <p>First episode (n) = 202 Recurrent episode (n) = 69</p> <p>Mean age (SD) First: 61 (±14) years Recurrent: 62 (±13) years</p> <p>Gender (male) First: 48% Recurrent: 45%</p>
Prognostic variable	Recurrent diverticulitis
Confounders/ Stratification strategy	The two groups were similar regarding age and sex ratio.
Outcomes and effect sizes	<p>Mortality Peto OR: 0.25 (95% CI 0.04 to 1.63)</p> <p>Surgery OR: 3.06 (95% CI 1.04 to 8.99)</p>

Reference	Pittet 2009⁴⁹
	Presence of abscess OR: 1.11 (95% CI 0.51 to 2.4)
Comments	Risk of bias: high – statistical analysis.

1 **Appendix E: Forest plots**

2 **E.1 Recurrent diverticulitis**

Figure 2: Mortality




Figure 3: Need for surgery





Figure 4: Presence of abscess of CT scan



3

4

Appendix F: GRADE tables

Table 18: Clinical evidence profile: Recurrent diverticulitis

Quality assessment							Effect	Quality
Number of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations (including publication bias where possible)	Pooled effect (95% CI)	
Mortality								
1	Cohort study	serious ¹	none	no serious indirectness	serious ²	Univariate analysis. Groups were similar regarding confounding factors.	Peto OR: 0.25 (95% CI 0.04 to 1.63)	LOW
Need for surgery								
1	Cohort study	serious ¹	none	no serious indirectness	none	Univariate analysis. Groups were similar regarding confounding factors.	OR: 3.06 (95% CI 1.04 to 8.99)	MODERATE
Presence of abscess								
1	Cohort study	serious ¹	none	no serious indirectness	serious ²	Univariate analysis. Groups were similar regarding confounding factors.	OR: 1.11 (95% CI 0.51 to 2.4)	LOW

¹ Methods: univariate analysis, the two groups were similar regarding age and sex ratio.


² 95% CI around the median crosses null line.

© NICE 2019. All rights reserved. Subject to Notice of rights.
1
2
35
3
4
5
6
7
8

1
2

Appendix G: Health economic evidence selection

Figure 5: Flow chart of health economic study selection for the guideline



* Non-relevant population, intervention, comparison, design or setting; non-English language

- 3 3.4 Non-surgical treatment of acute diverticulitis (Evidence review H)
4 3.6.1 Timing of surgery (Evidence review J)
5 3.6.2 Laparoscopic versus open resection (Evidence review K)
6 3.6.4 Primary versus secondary anastomosis (Evidence review M)
7 3.8 Laparoscopic lavage versus resection for perforated diverticulitis (Evidence review O)
8 3.9 Management of recurrent diverticulitis (Evidence review P)

Appendix H: Excluded studies

H.1 Excluded clinical studies

Table 19: Studies excluded from the clinical review

Reference	Reason for exclusion
Abbas 2007 ¹	Excluded due to incorrect comparison
Alvarez 2009 ²	Excluded due to incorrect comparison/analysis
Ambrosetti 1996 ³	Excluded due to incorrect analysis
Ambrosetti 1994 ⁴	Excluded due to incorrect comparison/analysis
Ames 2009 ⁵	Excluded due to incorrect comparison/analysis
Amin 1984 ⁶	Excluded due to incorrect comparison/analysis
Andeweg 2016 ⁷	Excluded due to incorrect Intervention
Anonymous 2002 ⁸	Excluded due to incorrect study design
Aydinli 2017 ⁹	Excluded due to incorrect comparison/analysis
Bauer 2009 ¹⁰	Excluded due to incorrect study design
Bielecki 2002 ¹¹	Excluded due to incorrect comparison/analysis
Biondo 2012 ¹²	Excluded due to incorrect comparison
Bohm 2015 ¹³	Excluded due to incorrect study design
Bolkenstein 2017 ¹⁴	Excluded due to incorrect comparison/analysis
Broderick-Villa 2005 ¹⁵	Excluded due to incorrect comparison
Carpenter 1972 ¹⁶	Excluded due to incorrect study design
Ceresoli 2017 ¹⁷	Excluded due to incorrect study design
Chapman 2005 ¹⁸	Excluded due to no relevant outcome
Chapman 2006 ¹⁹	Excluded due to incorrect comparison/analysis
Chiu 2001 ²⁰	Excluded due to incorrect Intervention
Damle 2014 ²¹	Excluded due to inappropriate review population
Deenichin 2008 ²²	Excluded due to incorrect comparison/analysis
Elliott 1997 ²³	Excluded due to incorrect analysis
Gala 2014 ²⁴	Excluded due to incorrect study design
Garfinkle 2016 ²⁵	Excluded due to incorrect comparison/analysis
Gregersen 2016 ²⁶	Excluded due to incorrect comparison/analysis
Haglund 1979 ²⁷	Excluded due to incorrect Intervention
Himal 1977 ²⁸	Excluded due to incorrect comparison/analysis
Howe 1979 ²⁹	Excluded due to incorrect comparison/analysis
Hussain 2008 ³⁰	Excluded due to incorrect comparison/analysis
Isbister 1997 ³¹	Excluded due to incorrect comparison/analysis
Jalouta 2017 ³²	Excluded due to incorrect comparison/analysis
Jamal Talabani 2016 ³³	Excluded due to no relevant outcome
Janes 2009 ³⁴	Excluded due to incorrect study design
Kaewlai 2007 ³⁵	Excluded due to incorrect comparison/analysis
Kakodkar 2005 ³⁶	Excluded due to incorrect comparison
Kiani 2015 ³⁷	Excluded due to inappropriate review population
Kronborg 1993 ³⁸	Excluded due to incorrect comparison
Ladwa 2012 ³⁹	Excluded due to abstract only
Lahat 2013 ⁴⁰	Excluded due to incorrect analysis
Lanas 2011 ⁴¹	Excluded due to incorrect not review population
Medina 1991 ⁴²	Excluded due to incorrect comparison

Reference	Reason for exclusion
Nelson 2008 ⁴⁴	Excluded due to incorrect analysis
Niebling 2013 ⁴⁵	Excluded due to incorrect comparison/analysis
Nishikawa 2013 ⁴⁶	Excluded due to incorrect comparison/analysis
Nord 1995 ⁴⁷	Excluded due to abstract only
O'Leary 2013 ⁴⁸	Excluded due to incorrect comparison/analysis
Rahbour 2013 ⁵⁰	Excluded due to incorrect comparison/analysis
Shah 2011 ⁵¹	Excluded due to incorrect comparison/analysis
Solkar 2005 ⁵²	Excluded due to incorrect comparison/analysis
Soreide 2016 ⁵³	Excluded due to incorrect study design
Thorson 2012 ⁵⁴	Excluded due to systematic review with irrelevant PICO
Vasilevsky 1998 ⁵⁵	Excluded due to incorrect comparison/analysis
Vinas-Salas 2001 ⁵⁶	Excluded due to incorrect comparison/analysis
Wood 1977 ⁵⁷	Excluded due to incorrect comparison/analysis

1

2